COR · CIK 0001140859
What Cencora, Inc. told the SEC could break it.
Cencora's dominant exposure is customer concentration: its top ten customers were about 66% of fiscal 2025 revenue, and just two — Walgreens/Boots at roughly 25% and Evernorth at about 13% — together accounted for 38%, so the loss of either relationship would materially dent revenue. As a national pharmaceutical distributor, it also continues to carry opioid-litigation exposure tied to the 2021 national Distributor Settlement, recording $60.7 million of related charges in fiscal 2025 (down from $227 million the prior year). A smaller, recurring drag comes from abroad: its International Healthcare Solutions segment absorbs roughly $50 million a year in hyperinflationary accounting effects from its Turkey operations.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- top 10 customers (including WBA, Evernorth) represent 66% of revenue; two named customers together are 38%high
Cencora's top 10 customers account for ~66% of revenue in FY2025; Walgreens/Boots at ~25% and Evernorth at ~13% together constitute 38% of revenue, creating significant concentration risk if either relationship is terminated.
“Our top 10 customers, including governmental agencies and group purchasing organizations ("GPO"), represented approximately 66% of revenue in fiscal 2025. In fiscal 2025, Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services accounted for approximately 13% of revenue. The loss of any key customer or GPO relationship could adversely affect future revenue and results of operations.”
SEC filing →As of 2025
Litigation
- opioid litigation — ongoing charges ($60.7M in FY2025, $227M in FY2024)medium
Cencora continues to incur opioid-related litigation charges — $60.7M in FY2025 and $227M in FY2024 — reflecting an ongoing exposure as a national pharmaceutical distributor that was party to the 2021 national opioid Distributor Settlement Agreement.
“Litigation and opioid-related credit (60,671) (227,070)”
SEC filing →As of 2025
Geographic concentration
- Turkey hyperinflationary impact — ~$50M annual drag on International Healthcare Solutionslow
Cencora's International Healthcare Solutions segment records ~$49-54M annually in Turkey hyperinflationary accounting impacts, a consistent headwind from its Turkey-based operations.
“Turkey highly inflationary impact (49,571) (54,087)”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Evernorth Health Services (Cigna)
“In fiscal 2025, Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services accounted for approximately 13% of revenue. The loss of any key customer or GPO relationship could adversely affect future revenue and results of operations.”
Cited →“In fiscal 2025, Walgreens and Boots together accounted for approximately 25% of revenue and Evernorth Health Services accounted for approximately 13% of revenue. The loss of any key customer or GPO relationship could adversely affect future revenue and results of operations.”
Cited →
Its suppliers
Elanco Animal Health Incorporated
“Our largest customer, an affiliate of Cencora, Inc., is a third-party veterinary distributor and represented approximately 12% of our total revenue in 2025.”
Cited →“McKesson, Inc. 25 % 23 % 16 % Cencora, Inc. 16 % 17 % 12 % Cardinal Health, Inc. 13 % 14 % 10 % Collectively, our three largest U.S. wholesaler customers represented 40 % and 34 % of total trade accounts receivab”
Cited →“For the year ended December 31, 2025, our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of our consolidated net revenue.”
Cited →“al Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States. No individual wholesaler accounted for greater than 43% of AbbVie's 2025 gross revenues in the United States.”
Cited →“Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2025, 2024 and 2023.”
Cited →“for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.”
Cited →“The table below displays the percentage of consolidated net sales to our largest customers during the years ended December 31, 2025, 2024 and 2023: Percentage of Consolidated Net Sales 2025 2024 2023 McKesson Corporation * * 10 % Cencora, Inc. 11 % 12 % 10 % Cardinal Health, Inc. * * 5 %”
Cited →“Cardinal Health, Inc. (“Cardinal Health”) 29 % 29 % 28 % Cencora, Inc. (“Cencora”) 21 % 21 % 22 % McKesson Corporation (“Mc”
Cited →“McKesson Corporation 42% 45% Cencora Inc. 19% 20% Cardinal Health, Inc. * 13% Lilly 14% —% Kissei * 11%”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch